AI-generated summary
This Cochrane review assessed second-generation antidepressants for seasonal affective disorder, pooling three randomised trials of fluoxetine and light therapy. The authors report that evidence on effectiveness was very limited, with a non-significant benefit over placebo and roughly equal results versus light therapy in two small trials. Data on adverse events were sparse, so no firm conclusions could be drawn.
- Participants
- 204
- Studies included
- 3
- Who or what was studied
- Adults with seasonal affective disorder (DSM criteria), mostly female, mean age 34 to 42 years
- Limits stated in the abstract
- Only three small, short RCTs were included, adverse event data were crude and not robust, and the authors state that larger trials are needed.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on doi.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Adverse event, Meta-analysis, Randomized controlled trial, Confidence interval, Risk of bias, Depression. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.